ISSN:
1432-1041
Source:
Springer Online Journal Archives 1860-2000
Topics:
Chemistry and Pharmacology
,
Medicine
Notes:
Summary Twenty-six Swiss physicians took part in a study in which the effects of an orally administered new beta-receptor blocking agent, Trasicor®, were assessed in out-patients with disturbances of cardiac rhythm. Ninety-eight patients were treated for 3 weeks with daily doses ranging from 20 to 120 mg, the most commonly employed daily dose being 60 mg. The patients were examined before treatment and again after 1, 3, 7, 14 and 21 days of treatment. The compound proved highly effective in decreasing heart rate in sinus tachycardia and ventricular rate in chronic auricular fibrillation, both at rest and during effort. Trasicor also abolished, or substantially reduced, the frequency of attacks of paroxysmal supraventricular tachycardia and ventricular ectopic beats. — In hypertensive patients, Trasicor elicited a statistically significant decrease in both the systolic and diastolic blood pressures, whereas in normotensives only the systolic blood pressure was affected to a statistically significant extent. - Side effects were usually mild and transient; treatment had to be withdrawn in only a small percentage of patients.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF00404658
